Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

NCT07443956 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether combining biologic therapy with anti-obesity treatments in people with psoriatic arthritis and excess weight can help understand how weight loss may influence disease-related changes in skin, joint, and fat tissues.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 45 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-03 · est. completion 2030-05

Where 4 sites · United Kingdom

What this study is testing ClinicalTrials.gov NCT07443956 ↗

Description as written by the study sponsor.

This is a trial to find out how weight loss (achieved by the use of tirzepatide) or ixekizumab treatment affects the characteristics of skin, joint and fat tissues in patients with Psoriatic Arthritis, Psoriasis and obesity/overweight BMI \>=27. Participants will be allocated either Tirzepatide, Ixekizumab or both. Samples of joint tissue, fat and skin will be taken at the start of the study and week 12. Blood and urine samples will also be taken. The primary objective will be to assess the changes seen in the joint, fat and skin tissue samples 12 weeks after starting the medications (additional analysis will be done on the optional 36 week samples). Secondary objectives will be * To assess the changes seen in blood 4, 12, 36 and 52 weeks after starting the medication. * To compare the changes seen in tissue and blood between Ixekizumab and Tirzepatide/Weight loss. * To see how the changes seen in the tissue relate to weight loss.

Treatments tested

Ixekizumab Drug

anti-IL17A monoclonal antibody
Tirzepatide Drug

GLP-1 and GIP agonist

Main thing measured	Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss
Sponsor	NHS Greater Glasgow and Clyde
Conditions studied	Psoriatic Arthritis (PsA), Obesity & Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07443956 ↗